You know, earnings from early biotechs are always bad, I think mbrx had more going on than anticipated. I hope with their 3 (?) Possible drug candidates it isnt a double edged sword, where they need to burn 3 times the cash in trials which causes that much more dilution. Obviously odds of success improve but at what cost.
News 
Market Data 
Discover 
